Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.


Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
P84077

UPID:
ARF1_HUMAN

ALTERNATIVE NAMES:
-

ALTERNATIVE UPACC:
P84077; P10947; P32889

BACKGROUND:
The ADP-ribosylation factor 1 is crucial for modulating vesicle trafficking and uncoating within the Golgi apparatus. Its activation state, controlled by GTP binding, is essential for the recruitment and release of coatomer proteins, impacting protein secretion processes. Beyond its primary function, ARF1 also plays a role in synaptic plasticity and spine morphology by modulating PICK1-mediated inhibition of the Arp2/3 complex, crucial for AMPA receptor trafficking.

THERAPEUTIC SIGNIFICANCE:
Given ARF1's critical role in Periventricular nodular heterotopia 8, a disorder marked by abnormal neuronal migration and severe neurological manifestations, elucidating ARF1's functions opens doors to potential therapeutic strategies. Targeting ARF1-related pathways could offer novel approaches for treating this and possibly other related neurological disorders.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.